Enliven Therapeutics, Inc. (ELVN)
(Delayed Data from NSDQ)
$21.88 USD
-0.34 (-1.53%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $21.88 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ELVN 21.88 -0.34(-1.53%)
Will ELVN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ELVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELVN
Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet
3 Stocks in the Limelight on New Analyst Coverage
ELVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELVN
Ex-congressional candidate and FTX executive's romantic partner indicted on campaign finance charges
Enliven price target raised by $5 at Mizuho, here's why
Enliven Therapeutics GAAP EPS of -$0.41
Buy Rating for Enliven Therapeutics Backed by Promising Clinical Data and Market Potential
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update